59 results about "Kynurenine" patented technology

Provided is a method for using low molecular weight compounds found in the body as a biomarker for diagnosing depression. Specifically, more than one compound selected from a group comprising the following are used: ADP-ribose, ATP, ADP, AMP, serotonin, tryptophan, kynurenine, SDMA (symmetrical dimethylarginine), threonine, glyceric acid, serine, N-acetylaspartic acid, glutamic acid, trigonelline, creatine, 2-methylserine, sphingosine, homovanillic acid, piperidine, sulfoxidized methionine, pipecolic acid, sphinganine, gamma-butyrobetaine, guanidinoacetic acid, isobutyric acid, creatinine, sarcosine, 3-methylbutyric acid, nicotinamide, betaine, ornithine, carnitine, ethanolamine, phosphoethanolamine, taurine, hypotaurine, aspartic acid, methionine, and tyrosine.

Disclosed is a nitrogen-containing heterocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof, which has kynurenine production inhibitory activity. (In formula (I), R6 and R7 may be the same or different and each represents a hydrogen atom or the like; R8, R9, R10 and R11 may be the same or different and each represents a hydrogen atom or the like; R1 represents a lower alkyl group which may be substituted by a cycloalkyl group, or the like; and R3 represents an optionally substituted aryl group or an optionally substituted heterocyclic group.)

The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp / kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression.

The invention relates to a method for simultaneously determining tryptophan, kynurenine and kynurenicacid by using high performance liquid chromatography-fluorescence method, which comprises the following steps: a. Hypersil C18 chromatographic column (250x4.6mm, particle size of 7 Mum) is adopted; b. each liter mobile phase contains 0.2 mol of zinc acetate, 8.3mol of acetic acid and 2.5v / v% of acetonitrile; c. flow velocity is 1.5ml / mim, sample size is 20 Mul, column temperature is 25 DEG C; and d. adjustable wavelength is set under the following conditions: at 0-11min, excitation wavelength is 365nm, emission wavelength is 480nm; at 11-15.5 min, excitation wavelength is 344nm, emission wavelength is 404nm; and at 5-20min, excitation wavelength is 254nm, and emission wavelength is 404nm. The method has simple method, quick separation, no derivation pre-column and post-column, high sensitivity and real and accurate result, and can simultaneously determine tryptophan, kynurenine and kynurenicacid.

The invention relates to a method for detecting small-molecule metabolic markers in the peripheral blood of aortic dissection, and its application. Combined chromatography and mass spectrometry are employed for high-flux large-scale metabonomic analysis of patients with aortic dissection to determine small-molecule metabolic profiling of the peripheral blood of the aortic dissection, and three small-molecule metabolic markers with greatest difference is obtained, wherein the three small-molecule metabolic markers are N1-acetyl-N2-formyl-5-methoxy kynurenine, glycerophosphorylcholine and 2-mercaptohistidine betaine. The invention provides a simple, low-harm and cheap method for screening and diagnosis of aortic dissection, and effective reference bases can be provided for diagnosis of clinical patients and assessment of the treatment efficacy of drugs.

Provided are methods for synthesizing compounds, including chiral kynurenine compounds. The methods are suitable for large-scale manufacture and produce the chiral kynurenines compounds in high chemical purity and high chiral purity.

This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine / kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase and / or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.

The invention provides a bladder cancer diagnosis marker which comprises inosine, N-acetyl-N-2-formyl-5-methoxy kynurenine and phosphatidylserine (O-18: 0 / 0: 0). A diagnosis index for a low-level bladder cancer and a high-level bladder cancer can be built through combination of human serum inosine, N-acetyl-N-2-formyl-5-methoxy kynurenine and phosphatidylserine (O-18: 0 / 0: 0), and accurate and fast diagnosis is carried out on the bladder cancer. The invention further provides application of the bladder cancer diagnosis marker in preparation of the bladder cancer diagnosis kit. In addition, the invention further provides the bladder cancer diagnosis kit. The bladder cancer diagnosis marker is capable of accurately judging the bladder cancer and accurately distinguishing the low-level bladder cancer from the high-level bladder cancer; the accuracy of the diagnosis result is high; and the quantizable, objective and sensitive clinical diagnosis index is provided for diagnosis of the bladder cancer.

Provided are methods for the synthesis of compounds including chiral kynurenine compounds, intermediates useful for the synthesis thereof, and related compounds. For example, methods are provided for the synthesis of L-4-chlorokynurenine.

The invention relates to the technical field of traditional Chinese medicines, in particular to a gegen-qinlian decoction water extract for regulating an obese body. The gegen-qinlian decoction waterextract is obtained from puerarin, radix scutellariae, coptidis rhizome and radix liquiritiae through medicinal material compatibility and water decoction; the medicinal material compatibility is calculated by the following materials in parts by mass: 7-9 parts of the puerarin, 2-4 parts of the radix scutellariae, 2-4 parts of the coptidis rhizome, and 1-3 parts of the radix liquiritiae; the gegen-qinlian decoction water extract is used for preparing drugs to regulate intestinal flora and liver biological clock genes of intestine damp heat of the obese body, and has the effect of reversing Akkermansia and Lactobacillus, at the same time, the expression and transcription level of liver Clock and Arntl genes is up-regulated, the level of body serum triglyceride can be effectively reduced, and the gegen-qinlian decoction water extract has a regulatory effect on total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, blood glucose, insulin and other blood lipid and blood glucose indexes, and also has a regulatory effect on short chain, medium chain and long chain fatty acids, tryptophan, kynurenine, cannabinoid and other metabolites of the body.

The invention belongs to the technical field of drug detection, and particularly relates to a method for directly determining three degradation products of tryptophan in a compound amino acid injection. The three degradation products of tryptophan refer to dioxindole alanine, kynurenine and 2-hydroxytryptophan. The method comprises the following specific steps: (1) preparing the following chromatographic conditions of a liquid chromatograph: a chromatographic column being an octadecylsilane chemically bonded silica chromatographic column; a mobile phase comprising a mobile phase A being a phosphate buffer solution and a mobile phase B being acetonitrile; the flow rate being 0.95-1.05 mL / min; the column temperature being 25-35 DEG C; the sample size being 5-100 [mu]L; gradient elution; andthe detection wavelength being 254 nm; (2) preparing a test solution; (3) preparing a reference substance solution; and (4) determining. The method has the advantages of strong specificity, high sensitivity and good repeatability, solves the technical problems of interference of other amino acid components in the prescription, inaccurate determination result caused by derivative reaction in otherdetection methods, and the like, and ensures the product quality.

The invention discloses a kit and a method for simultaneously detecting tryptophan and metabolites thereof in a biological sample based on ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS), which belong to the technical field of UPLC-MS / MS detection. The kit comprises standard substances of tryptophan and metabolites of the tryptophan, and the tryptophan and the metabolites of the tryptophan comprise 3-hydroxyl kynurenine, 5-hydroxytryptamine, kynurenine, yellow uric acid, tryptophan, kynurenic acid, 3-hydroxyl o-aminobenzoic acid, 5-hydroxyl indoleacetic acid, 3-indoleacetic acid and 3-indolepropionic acid. According to the method, the tryptophan and the metabolites of the tryptophan are detected by utilizing UPLC-MS / MS, and a standard curve is established according to a peak area, so that the contents of the tryptophan and the metabolites of the tryptophan are obtained. The method for detecting the tryptophan and the metabolites of the tryptophan is simple to operate, has the characteristics of high sensitivity, good selectivity and the like, can accurately and quickly detect the tryptophan and the metabolites of the tryptophan at the same time, and has wide application value.

The invention relates to the technical field of biological medicine. The invention provides an immune polypeptide and application thereof, the immune polypeptide is obtained by connecting an end-capping group and a short peptide, and the short peptide is one or more of GFFY, GDFDFDY and DPPA-1. The immune polypeptide can be self-assembled to form a supramolecular nano-drug. After entering a tumor microenvironment, the supramolecular nano-drug can simultaneously reverse an immunosuppressive effect mediated by accumulation of metabolites such as excessive consumption of tryptophan and kynurenine in an IDO pathway; the nano-drug can be specifically combined with PD-L1 on the surface of cancer cells to block immune escape of tumor cells; meanwhile, the immune response of the organism is activated and enhanced, the three parts play a role in parallel, so that the organism generates strong immune response aiming at tumors, the optimal effect is achieved in cancer immunotherapy, and a new thought is provided for developing multifunctional tumor immunotherapy nano-drugs.

The invention belongs to the field of disease diagnostic kit, and more specifically relates to applications of a set of amino acid markers in preparation of an acute kidney injury (AKI) diagnostic agent or a kit. The amino acid marker is one or a composition of two selected from kynurenine, hippuric acid, and pidolic acid. The AUC values of the three amino acid markers in independent diagnosis ofacute kidney injury at acute renal injury early stage diagnosis are all larger than 0.7, the diagnosis distinguish effect is excellent. The diagnosis capacities of kynurenine and hippuric acid are better than that of clinically used renal function marker creatinine and early stage diagnosis marker NGAL; the diagnosis time of the above three amino acids on AKI is earlier than that of clinically used renal function marker urea nitrogen. The invention also provides a targeting amino acid metabonomic detection method capable of realizing quantitative analysis of a plurality of amino acids at the same time, the sensitivity is high, and the results are accurate and reliable.

Provided is a method for using low molecular weight compounds found in the body as a biomarker for diagnosing depression. Specifically, more than one compound selected from a group comprising the following are used: ADP-ribose, ATP, ADP, AMP, serotonin, tryptophan, kynurenine, SDMA (symmetrical dimethylarginine), threonine, glyceric acid, serine, N-acetylaspartic acid, glutamic acid, trigonelline, creatine, 2-methylserine, sphingosine, homovanillic acid, piperidine, sulfoxidized methionine, pipecolic acid, sphinganine, gamma-butyrobetaine, guanidinoacetic acid, isobutyric acid, creatinine, sarcosine, 3-methylbutyric acid, nicotinamide, betaine, ornithine, carnitine, ethanolamine, phosphoethanolamine, taurine, hypotaurine, aspartic acid, methionine, and tyrosine.

This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine / kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase and / or modulating N-methyl-D-aspartate (NMDA) channel activities for the treatment of neurodegenerative and other disorders.

The invention discloses a method for preparing kynurenine from horseshoe crab tails.The method comprises the following steps of preparation of dry horseshoe crab tail powder, preparation of horseshoe crab tail crude extract, primary separation and purification of the horseshoe crab tail crude extract, separation and purification of a component A8 and separation and purification of components A8-24, wherein separation and purification of the components A8-24 comprise the steps that an appropriate amount of components A8-24 are taken, methyl alcohol is added for dissolution, and normal phase column separation is conducted; 50 mg of samples are taken and stirred with 150 mg of silica gel powder, 5 g of silica gel is saturated with petroleum ether and then subjected to column packing, after the the samples are packed in a column, elution is conducted with petroleum ether and acetone, when the ratio of petroleum ether to acetone is 1:10, fractions are collected, the number of the fractions is 60, the fractions from the 25 tube to the 40 tube are merged, after the the fractions are merged, vacuum concentration is conducted, and after solvent is dried out, kynurenine is obtained.According to the method for preparing kynurenine from the horseshoe crab tails, kynurenine is separated from the horseshoe crab tails for the first time, and kynurenine serving as the active ingredient of the horseshoe crab tails has great significance in secondary development of horseshoe crab tails.

The invention relates to a hydrothorax microparticle metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The pleural effusion microparticle metabolite composition for diagnosing tuberculous pleurisy comprises phenylalanine, tyrosine, methionine, kynurenine, lauroyl carnitine, glycine-binding chenodeoxycholic acid, phosphatidylcholine with the ratio of 36: 7 and lysophosphatidylcholine with the ratio of 20: 2. The kit for diagnosing tuberculous pleurisy comprises an internal standard substance for detecting the concentration of metabolites in the pleural effusion microparticle sample extraction solution. A combined marker provided by the invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, at the same time, can be complementary with a traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.

The invention relates to the field of biomedicine, and specifically to a diagnostic marker of a Parkinson's disease and application thereof. Up-regulated expression of kynurenine in the urine of a patient suffering from the Parkinson's disease is found for the first time, which suggests that the detection of expression level of the kynurenine has become one of the indicators for early diagnosis ofthe Parkinson's disease, thus confirming that the kynurenine can be used as a diagnostic marker of the Parkinson's disease, and providing a new direction for the diagnosis of the Parkinson's disease.

The invention belongs to the technical field of biological medicines, and particularly relates to an experimental method for rapidly detecting the activity of a human mesenchymal stem cell IDO1. The experimental method for rapidly detecting the activity of the human mesenchymal stem cell IDO1 comprises the following steps of: S1, culturing human mesenchymal stem cells; and S2, taking supernatant, and detecting the activity of indoleamine 2, 3-dioxygenase 1. By improving and optimizing a human mesenchymal stem cell culture method, the phenomena of cell adherence, quantity reduction and the like caused by high-density inoculation before cells are solved, so that the accuracy of a detection result is improved, and the accurate estimation and evaluation of the immune regulation and control function of the human mesenchymal stem cells are improved; and by determining a kynurenine solution, a trichloroacetic acid solution and a dimethylaminobenzaldehyde solution and selecting the mass concentration of the solutions, the evaluation accuracy of the function of the human mesenchymal stem cells is further improved.

The present invention is a kit for the determination of a neurodegenerative disease wherein separately from each other the content of kynurenine and kynurenic acid in a body fluid is determined and the quotient of the content of kynurenine to the content of kynurenic acid is calculated.

A process for converting tryptophan into kynurenine. The conversion of tryptophan into kynurenine is carried out by irradiating a substance comprising tryptophan with electromagnetic radiation comprising waves with wavelength in the range of 10 nanometer to 750 nanometer.

The invention belongs to the technical field of medicinal chemistry. The invention discloses linear peptide or cyclic peptide with the tumor cell inhibition activity. The linear peptide or cyclic peptide contains condensation fragments of kynurenine and arginine. A mass spectrum rapid positioning method for selectively identifying a cyclic peptide compound containing the kynurenine in complex extract is further used for separating and obtaining a new cyclic peptide compound with the antitumor activity from phakellia fusca thiele; and full synthesis of the compound is realized by applying solid-phase synthesis, liquid-phase cyclization and ozonation strategies in the final stage.

Presented herein are methods for treatment of diseases or conditions related to fibrosis. Compounds, or pharmaceutically acceptable salts thereof or pharmaceutical compositions thereof provide for the treatment of diseases or conditions related to fibrosis. The methods utilize the compounds kynurenine, kynurenic acid and xanthurenic acid, and various analogs, related structures and pharmaceutical compositions thereof, wherein the compounds are represented by one or more compounds represented by Formulas I, II, or II as set out below:

The invention provides a bladder cancer diagnosis marker which comprises inosine, N-acetyl-N-2-formyl-5-methoxy kynurenine and phosphatidylserine (O-18: 0 / 0: 0). A diagnosis index for a low-level bladder cancer and a high-level bladder cancer can be built through combination of human serum inosine, N-acetyl-N-2-formyl-5-methoxy kynurenine and phosphatidylserine (O-18: 0 / 0: 0), and accurate and fast diagnosis is carried out on the bladder cancer. The invention further provides application of the bladder cancer diagnosis marker in preparation of the bladder cancer diagnosis kit. In addition, the invention further provides the bladder cancer diagnosis kit. The bladder cancer diagnosis marker is capable of accurately judging the bladder cancer and accurately distinguishing the low-level bladder cancer from the high-level bladder cancer; the accuracy of the diagnosis result is high; and the quantizable, objective and sensitive clinical diagnosis index is provided for diagnosis of the bladder cancer.

The present invention addresses the problem of providing a novel therapeutic agent for an immune disease and a novel therapeutic agent for an anti-inflammatory agent. The present invention which can solve the problem is a mesenchymal stem cell characterized by being capable of producing kynurenine in a large amount or capable of secreting kynurenine in a large amount. The present invention also includes a mesenchymal stem cell which is characterized by being capable of producing kynurenine, which is synthesized from tryptophan with IDO induced in a cell by the treatment with IFNgamma, in a large amount or being capable of secreting the kynurenine in a large amount, and a mesenchymal stem cell which is characterized in that the JAK / STAT pathway thereof is enhanced in a steady state.

The invention belongs to the field of fresh-keeping solutions for tree peony cut flower, and particularly relates to a vase fresh-keeping liquid for tree peony cut flower. The vase fresh-keeping liquid for tree peony cut flower provided by the invention contains cane sugar, sodium hypochlorite, kynurenine and the balance of water. The tree peony cut flower fresh-keeping liquid has no pollution to human bodies and the environment, and is safe and harmless to the human bodies and the environment compared with a silver ion-containing fresh-keeping agent, an 8-HQ-containing fresh-keeping agent and the like which are frequently used as fresh-keeping components in the prior art. The tree peony cut flower fresh-keeping liquid provided by the invention is more rapid and convenient to use in the form of a bottle insertion fresh-keeping liquid than gases such as 1-MCP, ClO2 and the like as fresh-keeping components.

The invention relates to a hydrothorax fluid metabolite combination, a kit and a method for diagnosing tuberculous pleurisy. The hydrothorax fluid metabolite combination for diagnosing tuberculous pleurisy comprises dimethylglycine, tyrosine, kynurenine, nicotinamide, betaine, acylcarnitine with the ratio of 12: 0, acylcarnitine with the ratio of 14: 2 and phosphatidylcholine with the ratio of 42:8. The kit for diagnosing tuberculous pleurisy comprises an internal standard substance required for detecting the concentrations of dimethylglycine, tyrosine, kynurenine, nicotinamide, betaine, acylcarnitine with the ratio of 12: 0, acylcarnitine with the ratio of 14: 2 and phosphatidylcholine with the ratio of 42: 8 in a pleural effusion sample extraction solution. A combined marker provided bythe invention has the characteristics of high sensitivity and high specificity for the diagnosis of tuberculous pleurisy, meanwhile, can be complementary with the traditional marker adenosine deaminase, and can be used for the auxiliary diagnosis of the tuberculous pleurisy by being combined with the traditional marker adenosine deaminase.